Central News Agency (CNA reporter Su Ssu-yun, Taipei, July 1) The Ministry of Health and Welfare (MOHW) is recently planning a home chemotherapy policy, drawing public attention. The Life Insurers Association stated today that the applicability of commercial health insurance can only be assessed after the home chemotherapy policy planning becomes clear, and it is currently difficult to assess. According to current practical operations for home chemotherapy, as the initiation and completion are conducted in outpatient clinics, claims will be processed according to the policy if the individual has outpatient coverage. Home healthcare is becoming a trend, with even chemotherapy being completed in the familiar environment of home. Chen Liang-yu, Director-General of the National Health Insurance Administration (NHIA) of the MOHW, mentioned yesterday that the first phase is planned to include cancers such as stomach cancer and head and neck cancer. The current expert consensus is to use the chemotherapy drug 5-FU, commonly known as "baby bottle," with the earliest launch planned for the end of the year. The Life Insurers Association issued a press release today regarding the MOHW's plan to draw on international experience and promote home cancer treatment. It is understood that many physicians and medical professionals have reminded that home chemotherapy involves patients with poor self-care abilities and high risks in handling chemotherapy drugs, such as drug leakage and tube dislodgement. Corresponding emergency transfer and home medical waste disposal mechanisms are also needed to ensure the safety of patients receiving treatment at home. As the policy is not yet clear, the insurance industry finds it difficult to assess its applicability. The Life Insurers Association pointed out that according to current practical operations for home chemotherapy, chemotherapy drugs are mainly placed in outpatient clinics, and patients return home during the infusion period. After t